These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 6809453)

  • 41. [Spontaneous endogenous LH increase in the stimulated cycle].
    Alexander H; Birkhäuser M; Zimmermann G; Huber P; Pavic N; Lehmann M; Baier D; Weber W; Haake KW
    Arch Gynecol Obstet; 1989; 245(1-4):994-9. PubMed ID: 2508581
    [No Abstract]   [Full Text] [Related]  

  • 42. The role of color Doppler imaging in the diagnosis of polycystic ovary syndrome.
    Battaglia C; Artini PG; D'Ambrogio G; Genazzani AD; Genazzani AR
    Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):108-13. PubMed ID: 7847515
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The relative roles of exogenous and endogenous follicle-stimulating hormone (FSH) and luteinizing hormone (LH) in human follicular maturation and ovulation induction.
    Berger MJ; Taymor ML; Karam K; Nudemberg F
    Fertil Steril; 1972 Nov; 23(11):783-90. PubMed ID: 5082616
    [No Abstract]   [Full Text] [Related]  

  • 44. Blood flow changes in the ovarian and uterine arteries in women with polycystic ovary syndrome who respond to clomiphene citrate: correlation with serum hormone concentrations.
    Zaidi J; Jacobs H; Campbell S; Tan SL
    Ultrasound Obstet Gynecol; 1998 Sep; 12(3):188-96. PubMed ID: 9793191
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Endocrine studies of normal and polycystic ovarian tissues in vitro.
    Wilson EA; Erickson GF; Zarutski P; Finn AE; Tulchinsky D; Ryan KJ
    Am J Obstet Gynecol; 1979 May; 134(1):56-63. PubMed ID: 220877
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome.
    Falsetti L; Galbignani E
    Contraception; 1990 Dec; 42(6):611-9. PubMed ID: 2150631
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hormonal effects of flutamide in young women with polycystic ovary syndrome.
    De Leo V; Lanzetta D; D'Antona D; la Marca A; Morgante G
    J Clin Endocrinol Metab; 1998 Jan; 83(1):99-102. PubMed ID: 9435423
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The acute effect of hysterectomy on ovarian function.
    Stone SC; Dickey RP; Mickal A
    Am J Obstet Gynecol; 1975 Jan; 121(2):193-7. PubMed ID: 123120
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pituitary and ovarian function in women receiving hormonal contraception.
    Cohen BL; Katz M
    Contraception; 1979 Nov; 20(5):475-87. PubMed ID: 393456
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vaginal progesterone administration before ovulation induction with exogenous gonadotropins in polycystic ovarian syndrome.
    Buckler HM; Phillips SE; Cameron IT; Healy DL; Burger HG
    J Clin Endocrinol Metab; 1988 Aug; 67(2):300-6. PubMed ID: 3134388
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Syndrome of familial polycystic ovaries (Stein-Leventhal type): serum levels of luteinizing and follicle stimulating hormones before and after wedge resection of the ovaries].
    Toledo SP; Peña EP; Assis LM; Martorelli B; Mattar E
    AMB Rev Assoc Med Bras; 1977 May; 23(3):79-82. PubMed ID: 311042
    [No Abstract]   [Full Text] [Related]  

  • 52. Sex hormone profiles in oligomenorrheic adolescent girls and the effect of oral contraceptives.
    Siegberg R; Nilsson CG; Stenman UH; Widholm O
    Fertil Steril; 1984 Jun; 41(6):888-93. PubMed ID: 6233177
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of polycystic ovary disease with chronic low-dose follicle stimulating hormone: biochemical changes and ultrasound correlation.
    Seibel MM; Kamrava MM; McArdle C; Taymor ML
    Int J Fertil; 1984; 29(1):39-43. PubMed ID: 6146583
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gonadotropins, estrogens, and adrenal steroids during the menopausal hot flash.
    Meldrum DR; Tataryn IV; Frumar AM; Erlik Y; Lu KH; Judd HL
    J Clin Endocrinol Metab; 1980 Apr; 50(4):685-9. PubMed ID: 6444954
    [No Abstract]   [Full Text] [Related]  

  • 55. Androstenedione response to recombinant human FSH is the most valid predictor of the number of selected follicles in polycystic ovarian syndrome: (a case-control study).
    Ozyurek ES; Yoldemir T; Artar G
    J Ovarian Res; 2017 May; 10(1):34. PubMed ID: 28494798
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ovarian morphology as a predictor of hormonal values in polycystic ovary syndrome.
    van der Westhuizen S; van der Spuy ZM
    Ultrasound Obstet Gynecol; 1996 May; 7(5):335-41. PubMed ID: 8774098
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity.
    Rossmanith WG; Steffens D; Schramm G
    Contraception; 1997 Jul; 56(1):23-30. PubMed ID: 9306028
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
    Lemay A; Faure N; Labrie F; Fazekas AT
    Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Persistent anovulation following laparoscopic electrocoagulation of the ovarian surface in a patient with polycystic ovary syndrome (PCOS)].
    Nawroth F; Sudik R
    Zentralbl Gynakol; 1999; 121(3):156-8. PubMed ID: 10209860
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The hormonal response of patients with polycystic ovarian disease to subcutaneous low frequency pulsatile administration of luteinizing hormone-releasing hormone.
    Hurwitz A; Rosenn B; Palti Z; Ebstein B; Har-Nir R; Ron M
    Fertil Steril; 1986 Sep; 46(3):378-84. PubMed ID: 2943606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.